Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14761864 | 0.85 | TSHR (0.36) | TSHRNFKB1CYP2C19 | |
| SCHEMBL13618681 | 0.76 | TSHR (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL1698695 | 0.75 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL9301579 | 0.75 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL11741742 | 0.75 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10309988 | 0.73 | — | — | |
| SCHEMBL23453126 | 0.73 | TSHR (0.33) | TSHRNFKB1CYP2C19 | |
| SCHEMBL11145331 | 0.72 | OPRM1 (0.41) | — | |
| SCHEMBL24777519 | 0.70 | TSHR (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL13805885 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | ATR, MRE11, PARP2 | TSHR 2353/4885NFKB1 2933/4885CYP2C19 4420/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | TSHR 3884/4885NFKB1 2565/4885CYP2C19 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.